<DOC>
	<DOCNO>NCT01046682</DOCNO>
	<brief_summary>This phase II , open label , randomized-controlled pilot study design study efficacy safety salsalate decrease endothelial cell dysfunction , systemic inflammation , insulin resistance HIV-infected adult . The investigator hypothesis salsalate reduce inflammation therefore endothelial cell activation insulin resistance . The sample size 40 , equal number people randomize one two group . The first arm randomize salsalate therapy . The second arm act control group . The study duration 13 week .</brief_summary>
	<brief_title>Safety Efficacy Salsalate Treat Endothelial Dysfunction HIV-infected Adults</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Salicylsalicylic acid</mesh_term>
	<mesh_term>Sodium Salicylate</mesh_term>
	<criteria>1 . 18 year age old 2 . HIVinfected 3 . Evidence durable virologic suppression , i.e. , must HIV1 RNA &lt; 400 copies/ml study entry least 12 week prior entry 4 . On stable antiretroviral ( ARV ) regimen , i.e. , ARV least 12 week prior study entry 5 . No intention stop modify ARV regimen study period 1 . Current pregnancy breast feeding , woman child bear age refuse unable use appropriate method contraception study period 2 . Any following condition : diabetes ( 2 fast glucose level &gt; 126 mg/dL confirm random glucose level &gt; 200 ) , creatinine clearance &lt; 50 , aspirinsensitive asthma , COPD , history bleed gastric duodenal ulcer , hepatic dysfunction , active hepatitis B C , active infectious inflammatory condition 3 . Need regular use follow medication : salsalate , aspirin , nonsteroidal antiinflammatories ( NSAIDS ) , corticosteroid , warfarin anticoagulation therapy , phenytoin , valproic acid , carbonic anhydrase inhibitor , lithium , probenecid sulfinpyrazone 4 . Consumption alcohol daily basis 5 . Active use illicit drug 6 . Unable attend followup appointment 7 . Allergy salicylic acidcontaining medication salsalate 8 . AST ALT &gt; 2 upper limit normal ( ULN ) within 6 month prior study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>HIV</keyword>
	<keyword>Endothelial dysfunction</keyword>
	<keyword>Inflammation</keyword>
	<keyword>Insulin resistance</keyword>
</DOC>